Alkem Laboratories Limited
₹5,125.00+₹75.00 (+1.5%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹70,090 Cr
- P/E
- 31.4x
- EV / EBITDA
- 33.0x
- Revenue
- ₹8,813 Cr
- Net margin
- 21.9%
- ROCE
- 14.5%
Price chart
Technical chartScreen technicals →-7.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -0.4%
- 3M
- -11.9%
- 6M
- -5.2%
- 1Y
- -7.2%
- 5Y
- +40.5%
52-week range
Day change +₹75.00 (+1.5%) from ₹5,050 to ₹5,125 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ALKEM, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Healthy return on equity of 16.6%
Concerns1
- Slow revenue growth of 3.6% CAGR over 5 years
Rule-based from financial data. Not advice.
About the company
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally.
Read moreShow less
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 12.0 Cr shares
- ISIN
- INE540L01014
- BSE code
- 539523
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹70,090 Cr
- P/E
- 31.4x
- P/B
- 5.1x
- EV / EBITDA
- 33.0x
- EV / Sales
- 8.7x
- P/S
- 8.8x
- Earnings yield
- 3.2%
- 52-week high
- ₹5,887.85
- 52-week low
- ₹4,919.95
Profitability
- Operating margin
- 21.0%
- Net margin
- 21.9%
- EBITDA margin
- 26.4%
- ROE
- 16.6%
- ROCE
- 14.5%
- ROA
- 12.4%
- Dividend payout
- 27.0%
- Tax rate
- 2.0%
- Other income, % of PBT
- 23.9%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹8,813 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.6%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,100 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 27.8%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 30.6%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 6.7%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,687 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 17.4%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹145 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.3%
Solvency and efficiency
- Current ratio
- 4.91
- Debt / Equity
- 0.10
- Debt / Assets
- 0.07
- Debt / EBITDA
- 0.48
- Interest coverage
- 20.93
- Financial leverage
- 1.33
- CFO / Net profit
- 0.97
- Cash / Market cap
- 13.3%
- Cash per share
- ₹781.09
- Asset turnover
- 0.57
- Fixed asset turnover
- 4.47
- Capital intensity
- 0.22
- Debtor days
- 80 days
- Inventory turnover
- 1.42
- Cash conversion cycle
- 119 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹26 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹6,657 Cr |
| Sales | Operating profit | ₹2,156 Cr |
| Operating profit | Interest | ₹76 Cr |
| Operating profit | Depreciation | ₹284 Cr |
| Operating profit | Profit before tax | ₹1,796 Cr |
| Other income | Profit before tax | ₹698 Cr |
| Profit before tax | Tax and other | ₹214 Cr |
| Profit before tax | Net profit | ₹2,281 Cr |
Revenue and net profit
Revenue grew 10.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹7,220 Cr | ₹1,685 Cr |
| FY2022 | ₹8,830 Cr | ₹1,541 Cr |
| FY2023 | ₹9,055 Cr | ₹1,134 Cr |
| FY2024 | ₹7,964 Cr | ₹1,747 Cr |
| FY2025 | ₹8,813 Cr | ₹2,281 Cr |
Cash flows
FY2025: ₹2,189 Cr from operations, ₹1,182 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹1,324 Cr | ₹203 Cr |
| FY2022 | ₹1,299 Cr | -₹370 Cr |
| FY2023 | ₹1,437 Cr | ₹1,634 Cr |
| FY2024 | ₹1,687 Cr | ₹821 Cr |
| FY2025 | ₹2,189 Cr | ₹1,182 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹8,813 Cr+10.7%1Y
- Net profit
- ₹2,281 Cr+30.6%1Y
- Cash from operations
- ₹2,189 Cr
- Free cash flow
- ₹1,182 Cr+44.0%1Y
- Revenue CAGR, 5Y
- 3.6%
- EBITDA CAGR, 5Y
- 6.1%
- Net profit CAGR, 5Y
- 6.7%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹8,813 Cr | ₹2,156 Cr | — | ₹2,281 Cr | ₹2,189 Cr | ₹1,182 Cr | 18.5% | +10.7% | +30.6% |
Monthly returns
Month-by-month returns of ALKEM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹15,596 Cr |
| Equity capital | ₹24 Cr |
| Reserves | ₹12,298 Cr |
| Borrowings | ₹439 Cr |
| Other liabilities | ₹2,835 Cr |
| Assets | ₹15,596 Cr |
| Fixed assets | ₹1,591 Cr |
| Capital work in progress | ₹76 Cr |
| Investments | ₹4,407 Cr |
| Other assets | ₹9,521 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ALKEM trades at 31.4x earnings against a peer median of 52.6x (a 40% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Alkem Laboratories LimitedALKEMthis companyP/E ↓ discount | ₹70,090 Cr | 31.4x | 5.1x | 16.6% | 33.0x |
| Mankind Pharma LimitedMANKIND | ₹91,284 Cr | 54.8x | 5.9x | 19.3% | 34.3x |
| Zydus Lifesciences LimitedZYDUSLIFE | ₹90,637 Cr | 18.8x | 4.2x | 21.9% | 18.4x |
| Fortis Healthcare LtdFORTIS | ₹68,497 Cr | 370.0x | 7.4x | 2.2% | 160.8x |
| Aurobindo Pharma Ltd.AUROPHARMA | ₹67,835 Cr | 33.6x | 3.2x | 9.9% | 23.8x |
| Abbott India Ltd.ABBOTINDIA | ₹59,620 Cr | 39.5x | 14.9x | 32.5% | 34.5x |
| Laurus Labs LimitedLAURUSLABS | ₹57,182 Cr | 83.8x | 11.6x | 5.3% | 73.3x |
| Biocon Ltd.BIOCON | ₹56,868 Cr | 709.0x | 3.1x | 1.1% | 124.1x |
| Glenmark Pharmaceuticals ltdGLENMARK | ₹56,650 Cr | 38.5x | 2.4x | 22.5% | 7.3x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ALKEM since 1 January, against earlier years.
Historical volatility
ALKEM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 27.0% |
| FY2022 | 21.0% |
| FY2023 | 15.0% |
| FY2024 | 21.0% |
| FY2025 | 24.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹8,813 Cr |
| Costs | |
| Interest | ₹76 Cr |
| Expenses | ₹6,657 Cr |
| Operating profitOperating Profit | ₹2,156 Cr |
| Other income and charges | |
| Profit before tax | ₹2,495 Cr |
| Tax | |
| Net profitNet Profit | ₹2,281 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹15,596 Cr |
| Equity capitalEquity Capital | ₹24 Cr |
| Reserves | ₹12,298 Cr |
| Borrowings | ₹439 Cr |
| Other liabilitiesOther Liabilities | ₹2,835 Cr |
| AssetsTotal Assets | ₹15,596 Cr |
| Fixed assetsFixed Assets | ₹1,591 Cr |
| Capital work in progressCWIP | ₹76 Cr |
| Investments | ₹4,407 Cr |
| Other assetsOther Assets | ₹9,521 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹2,189 Cr |
| Investing cash flowCash from Investing Activity | -₹1,007 Cr |
| Financing cash flowCash from Financing Activity | -₹1,037 Cr |
| Change in cashNet Cash Flow | ₹145 Cr |
Learn while you research
Academy chapters picked for Alkem Laboratories Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 31.4, learn when high multiples are justified.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read